BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) is expected to announce its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($1.38) per share and revenue of $161.26 million for the quarter.

BioNTech Trading Down 0.1%

NASDAQ BNTX opened at $107.34 on Friday. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a market cap of $25.80 billion, a price-to-earnings ratio of -31.57 and a beta of 1.23. The business’s fifty day moving average is $108.11 and its 200 day moving average is $106.27.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BioNTech stock. Royal Bank of Canada lifted its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 95.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,177 shares of the company’s stock after acquiring an additional 3,514 shares during the period. Royal Bank of Canada’s holdings in BioNTech were worth $653,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on BNTX shares. Truist Financial reissued a “buy” rating and set a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, June 7th. HC Wainwright reissued a “buy” rating and set a $138.00 price objective on shares of BioNTech in a report on Wednesday, June 25th. JPMorgan Chase & Co. lowered their target price on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research report on Thursday, May 22nd. Finally, Morgan Stanley raised their target price on BioNTech from $132.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $136.58.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.